Despite the fact that radiation is one of the standard therapies in the treatment of patients with oral cancer, tumours can recur even in the early stages of the disease, negatively impacting prognosis and quality of life. We previously found that CD11b + bone marrow-derived cells (BMDCs) were recruited into human glioblastoma multiforme (GBM), leading to re-organization of the vasculature and tumour regrowth. However, it is not yet known how these cells contribute to tumour vascularization. In the present study, we investigated the role of infiltrating CD11b + myeloid cells in the vascularization and recurrence of oral squamous cell carcinoma (OSCC). In a xenograft mouse model, local irradiation caused vascular damage and hypoxia in the tumour and increased infiltration of CD11b + myeloid cells. These infiltrating cells showed characteristics of M2 macrophages (M2Mϕs) and are associated with the promotion of vascularization. M2Mϕs promoted tumour progression in recurrence after irradiation compared to non-irradiated tumours. In addition, we found that CD11b + myeloid cells, as well as CD206 + M2Mϕs, are increased during recurrence after radiotherapy in human OSCC specimens. Our findings may lead to the development of potential clinical biomarkers or treatment targets in irradiated OSCC patients.
. These data indicate that preventing angiogenesis is insufficient to inhibit tumour growth. Tumour vasculature is thought to be dependent on two principal factors. Angiogenesis is derived from the sprouting of endothelial cells from existing tumour vessels or nearby normal vessels 1 , and vasculogenesis is due to colonization of circulating endothelial progenitor cells (EPCs) or BMDCs 4 . Because tumour endothelial cells divide actively and are highly radiosensitive, it is unlikely that any of them could survive the doses given in a typical radiotherapy regimen. Thus, local irradiation may block the angiogenesis pathway, forcing tumour recurrence to rely on the vasculogenesis pathway.
We have previously shown in an intracranial GBM xenograft model that irradiation induces recruitment of BMDCs into tumours, restoring radiation-damaged vasculature by vasculogenesis and thus allowing the growth of surviving tumour cells 5 . Kozin et al . also demonstrated in lung and breast tumour models that host-derived BMDC infiltration in tumours was stimulated by local irradiation and facilitates tumour recurrence through paracrine effects on irradiated tumour vasculature 6 . Both studies indicated that CD11b + BMDCs, but not EPCs, make significant contributions to facilitate tumour regrowth after irradiation.
CD11b + myeloid cells recruited into tumours are thought to subsequently differentiate into macrophages. Macrophages surrounding the tumour are referred to as tumour-associated macrophages (TAMs), which are believed to act as key regulators of tumour angiogenesis, migration, metastasis, and treatment resistance 7 . Macrophages are also polarized into two specific phenotypes in response to signals present within individual microenvironments. Pro-inflammatory M1Mϕ s (classically activated), which are activated by LPS and IFN-gamma, secrete TNF-alpha, IL-12, IL-6 and inducible NO synthase (iNOS) and support T-cell function. In contrast, M2Mϕ s (alternatively activated), which are activated by IL-4 and IL-13, produce IL-10 and TGF-beta and down-regulate T-cell function. M2Mϕ s are thought to be anti-inflammatory and immunosuppressive. M1 and M2Mϕ s also have the ability to suppress and promote tumour progression, respectively 8 . Infiltrated TAMs in tumours are generally characterized as M2 phenotypes and promote tumour growth and vasculature [9] [10] [11] . Many clinical studies have also suggested a positive correlation between the number of TAMs and/or M2 profiles in a tumour and increased tumour angiogenesis and metastasis and poor prognosis in cancer patients [12] [13] [14] [15] [16] . Because monocytes should be polarized into macrophages in peripheral tissues, we hypothesized that CD11b
+ myeloid cells recruited into irradiated tumours may be differentiated into a proangiogenic phenotype of macrophages. Therefore, our research aimed to investigate whether CD11b + myeloid cells are recruited into oral cancer after irradiation and how they are differentiated into macrophages in relation to tumour relapse, which remains largely uncharacterized.
Results

Irradiation causes vascular damage and tumour hypoxia, leading to recruitment of CD11b
+ myeloid cells into OSCC tumours. To assess alterations in the tumour microenvironment following radiotherapy, we established an OSCC xenograft mouse model using OSC-19 cells. As shown in Fig. 1a , s.c. implanted tumours grew progressively; however, 12 Gy local irradiation caused the tumours to regress, followed by regrowth in several weeks. Tumour samples following irradiation were collected when the tumours grew back to their pre-irradiation sizes and were analysed by immunofluorescence staining to compare the influx of CD11b
+ cells with that of non-irradiated control tumours. We found that recurrences contained significantly higher numbers of CD11b
+ cells (Fig. 1b,c) . Similar results were obtained from other OSCC s.c. tumour models using HSC-3 (tongue) and YCU-OR891 (oral floor) cells (Supplementary Fig. S1 ).
The results of previous reports 5, 17, 18 suggested that CD11b + cell recruitment was induced by hypoxia. To test this, we investigated hypoxia levels in tumours using pimonidazole staining along with blood vessel staining in a time course analysis. We found that hypoxic areas were extended in the tumours, starting from two weeks after irradiation, and CD31
+ vascular endothelial cells were significantly reduced (Fig. 1d,e) . Interestingly, further analysis showed that the highest numbers of CD11b + cells were recruited at the same time point and were inversely proportional to CD31 density (Fig. 1f,g ). These data suggest that local tumour irradiation causes vascular damage and hence tumour hypoxia, which may be the stimulus for the recruitment of CD11b + cells into tumours.
Analysis of BMDC components in OSCC tumour-bearing mice. It was previously reported that monocyte precursors were increased in the BM, spleen and peripheral blood (PB) of tumour-bearing mice in various cancers 19, 20 . Therefore, we first determined the proportion of CD11b + cells in the PB and BM of normal mice and OSC-19 tumour-bearing mice by FACS analysis. In both the PB and the BM, the percentage of CD11b + cells obtained from OSC-19 tumour-bearing mice was significantly higher than that of cells from normal mice (Fig. 2a,b) . These data suggest that not only blood cells but also BMDCs may be altered by tumours, most likely by the secretion of cytokines and chemokines.
CD11b
+ dominant BMDCs accelerate new blood vessel formation in tumours at the initial stage when tumours were injected. We then investigated whether BMDCs of OSC-19 tumour-bearing mice with higher numbers of CD11b + cells affected cancer cell biology in vitro or tumour growth in vivo. To test this, OSC-19-luc cells were co-cultured with BMDCs of normal control mice or tumour-bearing mice, and the proliferation of OSC-19-luc cells was assessed by the IVIS system. The results showed no significant difference between the control and tumour-bearing BMDCs with respect to OSC-19 cell proliferation, suggesting that in spite of different CD11b positive rates, BMDCs have no effect on OSC-19 cell proliferation (Fig. 3a) .
We next examined the effect of BMDCs on the growth of OSC-19 s.c. tumours in nude mice. In this experiment, BMDCs derived from normal control mice or tumour-bearing mice were co-injected with OSC-19 cells into non-IR or pre-IR sites, in which irradiation eliminated pre-existing blood vessels, causing the "tumour bed effect" 21 . Tumour nodules were initially formed at both non-IR and pre-IR sites when OSC-19 cells were injected with BMDCs of tumour-bearing mice. At non-IR sites, OSC-19 tumours injected with BMDCs of tumour-bearing mice grew progressively in the early stages of tumour growth. In contrast, the tumours with BMDCs of tumour-bearing mice grew progressively over the period of the experiment at the pre-IR site (Fig. 3b) . We next examined blood vessel formation in the early stages of tumour growth in non-IR sites. We observed twice the density of CD31 endothelial cells in tumours when OSC-19 cells were co-injected with BMDCs of tumour-bearing mice as compared to those of normal control mice (Fig. 3c) . These results suggest that CD11b 
M2Mϕs are polarized from CD11b
+ myeloid cells in OSC-19 tumours after irradiation. We next characterized the CD11b + cells recruited into tumours after irradiation. Double immunostaining with CD11b and F4/80, Gr-1, Tie-2 or VEGFR2 revealed that CD11b + F4/80 + cells were the most common population, followed by CD11b + Gr-1 + cells. Subsets of CD11b + cells, however small the number, expressed Tie-2 antigen, categorizing them as Tie2-expressing macrophages (TEMs). TEMs have been reported to be highly proangiogenic and to interact with the formation of tumour blood vessels 22 . CD11b + VEGFR + circulating precursor cells that contribute to the structural luminal surface of capillaries were not detectable. These results indicate that recruited CD11b + cells are highly related to the macrophage lineage ( Fig. 4a,b) . We then analysed the characteristics of the macrophage lineage recruited in tumours. We found that CD68 + CD206 + M2Mϕ s were mainly localized in peritumoural areas and that their number in tumours after irradiation was significantly higher than those in non-irradiated controls (Fig. 4c,d ). We next analysed the number of M1 or M2Mϕ s in tumours, as shown in Fig. 3c . While M2Mϕ s were significantly induced in OSC-19 tumours co-injected with the BMDCs of tumour-bearing mice compared to that of normal mice, the number of M1Mϕ s was not significantly affected ( with BM-M2Mϕ s was promoted until day 18 in the non-IR site. Tumour growth at the pre-IR site was significantly accelerated in the presence of BM-M2Mϕ s over a long period compared to BM-M1Mϕ s or even tumour cells alone (Fig. 5b) . As shown in Fig. 5c , tumours with BM-M2Mϕ s at non-IR sites appeared haemorrhagic; therefore, we examined blood vessel formation. CD31
+ vessel cells were significantly increased in tumours when OSC-19 cells were co-injected with BM-M2Mϕ s compared to controls (Fig. 5d) . Furthermore, we investigated the role of BM-M2Mϕ s in blood vessel formation without cancer cells. As shown in Fig. 5e and Supplementary Fig.  S4 , BM-M2Mϕ s promoted tube-like formation in CD31
+ endothelial cells in a Matrigel plug assay in nude mice compared with controls. These results suggest that BM-M2Mϕ s enhance tumourigenicity by promoting tumour vasculature, especially when local endothelial cells are eradicated by irradiation.
The portion of CD11b
+ myeloid cells and M2Mϕs recruited into tumours after irradiation expresses IL-13Rα2. IL-13Rα 2, one of the IL-13 receptors, is highly expressed in some cancer cells, including GBM 23 and OSCC 24 ; therefore, targeting this receptor, such as CAR-T and IL13-PE, would be new strategy for these cancer patients 25 . Interestingly, recent reports have shown that macrophages recruited by inflammation in ulcerative colitis and pulmonary fibrosis also express IL-13Rα 2 26, 27 . We therefore investigated whether CD11b 6 cells) were co-injected with BMDCs (2 × 10 6 cells) of normal mice or OSC-19 tumour-bearing mice into non-IR or pre-IR sites of nude mice. Tumour size was measured on the indicated date. Data shown are means ± SEM, n = 5-7 per group. *P < 0.05; *** P < 0.001. (c) Quantification of CD31 density of IHC in the early stage (day10) of the tumour at non-IR site. Data shown are means ± SD. *** P < 0.001. Non-IR, non-irradiated; Pre-IR, previously-irradiated; BMDC, bone marrow-derived cell. cells and M2Mϕ s recruited into tumours following irradiation express IL-13Rα 2. To test our hypothesis, we examined the expression levels of IL-13Rα 2 in M1 and M2Mϕ s derived from WEHI274.1 cells and BMDCs. RT-PCR showed higher levels of IL-13Rα 2 expression in both M2Mϕ s (Fig. 5f) . Furthermore, we compared the IL-13Rα 2 expression in CD11b
+ cells recruited into OSC-19 tumours at non-IR and pre-IR sites by FACS analysis. Interestingly, the percentage of IL-13Rα 2 + cells in CD11b + cells in tumours grown at pre-IR sites was significantly higher than that of non-IR sites (Fig. 5g) . These results suggest that IL-13Rα 2 is a potent molecular target for the depletion or ablation of CD11b + cells and for M2Mϕ s to inhibit reorganization of blood vessels following radiation. + cells recruited into tumours grown at pre-IR sites was significantly higher than that at non-IR sites. Data shown are means ± SD, n = 6 per group. *** P < 0.001. BM-Mϕ , bone marrow-derived macrophage.
Scientific RepoRts | 6:27548 | DOI: 10.1038/srep27548 a mouse model in humoral tumour tissue specimens. Immunohistochemical analyses were performed using human OSCC specimens obtained from biopsy samples before treatment and from recurrent tumours after radiotherapy in the same individuals. We found higher levels of CD11b + cells in the recurrent tumours than in the untreated primary tumours in eight out of eleven paired samples (Fig. 6a,b) . We then further evaluated the expression of CD31, CD68, and CD206 in the same specimens and found that CD206 + M2Mϕ s was also increased in recurrences, while the recurrent tumours showed lower levels of CD31 vasculature (Fig. 6c) .
Discussion
The present study demonstrated that local irradiation promotes the influx of CD11b + myeloid cells into OSCC, followed by polarization towards M2Mϕ s, contributing to re-organization of the vascular network in the tumour. Data presented herein show for the first time that irradiation induces CD68 + CD206 + M2Mϕ s polarization that promotes neovascularization in OSCC in a mouse model.
We have shown that irradiation induces recruitment of CD11b + BMDCs into OSCC. This is consistent with previous studies showing that an increased influx of CD11b + cells was found in irradiated tumours in several cancer models 6, 15, 28 . We also previously reported in GBM specimens that there was a significant increase in CD11b + cell infiltration in recurrent tumours compared with their matched primary tumour specimens, which is consistent with our current OSCC data. The stimulus for this phenomenon is that increased tumour hypoxia occurred due to the loss of blood vessels. Hypoxia-inducible factor-1α (HIF-1α ) is a crucial factor in the induction of BMDC influx. Various animal studies showed that HIF-1α regulates many chemokines that may induce recruitment of BMDCs into tumours, including chemokine ligand 2 (CCL2 or MCP1) 29 , colony-stimulating factor-1 (CSF-1) [30] [31] [32] , and stromal-derived factor-1 (SDF-1) 5, 17 . The present study also demonstrates that hypoxia is prominently increased in OSC-19 tumours as it initiates recruitment of CD11b + cells into the tumour. Previous studies reported that CD11b + monocyte precursors were increased in the BM, spleen, and PB of tumour-bearing mice in colon adenocarcinoma, mammary adenocarcinoma, and lymphoma. Moreover, those immature myeloid cells are also further produced in the PB of patients with cancer 19, 20 . The increases in these cells in the PB are thought to be due to release from the BM by cytokines and chemokines secreted by tumour cells. We also found a higher proportion of CD11b + cells in the PB and BM of OSC-19 tumour-bearing mice, suggesting that BMDCs can be altered by tumours, likely secretory cytokines and chemokines.
BMDC accumulation in OSC-19 tumours after local irradiation was largely composed of CD11b + myeloid cells. Subclass analyses of these cells showed high co-expression of F4/80, indicating that they are of the macrophage lineage. TEMs, which have shown the proangiogenic activity of myeloid cells in tumours, were small in number, which is consistent with a previous report 22 . De Palma et al. demonstrated in mouse xenografts that conditional depletion of TEMs prevented angiogenesis and delayed tumour growth. We also reported that approximately half of the CD11b + myeloid cells recruited into the irradiated GBM were TEMs 5 . Inhibiting TEM recruitment into tumours by pharmacologically interfering with the CXCL12/CXCR4 axis increased the efficacy of radiation or vascular-disrupting agents in GBM and murine mammary tumours 5, 33 . However, inhibition of CXCL12 by AMD3100 had no effect on the regrowth of OSC-19 tumours after irradiation (data not shown), indicating that the proportion of TEMs and chemokine for recruitment is likely different from the types of histology, advancement, or location of the tumours. CD11b hi monocytic MDSCs in tumour relapse after radiation may not be excluded, CD11b
+ monocytic cells, but not CD11b + neutrophils or granulocytes, seem to be more critical as a proangiogenic population 28 . M2Mϕ s have been reported to have protumoural functions, including functions in angiogenesis and alterations in invasiveness. In our study, M2Mϕ s had no effect on OSC-19 cell proliferation in vitro, while they promoted tumour growth and regrowth in vivo. This effect was more significant and lasted much longer in tumours injected at pre-IR sites. CD31 endothelial cells in the tumours of non-IR sites showed that OSC-19 tumours injected with M2Mϕ s formed more blood vessels. These results suggested that the effect of M2Mϕ s on neovascularization acts in more ischaemic conditions and contributes to relapse in OSCC tumours. Indeed, in conditions such as wound and ischaemic heart disease models, polarization of the M2 phenotype is promoted in infiltrating macrophages. Oxygen deprivation functionally links to progressive induction of proangiogenic M2Mϕ s 35 . We have previously reported in a GBM model that tumour vascularization mainly relies on angiogenesis in normal conditions; however, when local irradiation inhibits angiogenesis and induces hypoxia, vasculogenesis predominates. In this study, CD31 endothelial cells decreased to 36% of control levels by 2 weeks after 12 Gy irradiation so that angiogenesis was inhibited by irradiation in an OSCC model. Because BMDCs of tumour-bearing mice also promoted tumour growth in non-IR sites, it is possible that angiogenesis was also stimulated. However, the effect of tumour-bearing BMDCs was limited to the initial stage of non-IR tumours and was more significant in pre-IR sites; therefore, BMDCs more likely contribute to vasculogenesis in irradiated tumours. Proangiogenic M2Mϕ s are reported to secrete several angiogenic factors, such as VEGF, IL-8 (CXCL8), bFGF (basic fibroblast growth factor), TP (thymidine phosphorylase), and MMP (matrix metalloproteinase) 11, 36 , recolonizing and stabilizing tumour vasculature after irradiation, thereby supporting any remaining viable tumour cells. However, the specific mechanism underlying this process is not well understood, and further studies will be necessary.
The observation of increased CD11b + myeloid cells in recurrence also has clinical implications. Evidence has accumulated suggesting that recruitment of myeloid cells into tumours is correlated with clinical outcomes accompanied by treatment. A previous study reported that macrophage density positively correlated with microvessel counts and negatively correlated with patient relapse-free survival in lung cancer 37 . Balermpas et al. also reported that CD163 + macrophage expression predicts an unfavourable clinical outcome in HNSCC after definitive chemoradiotherapy 15 . In the present study, CD206 + M2Mϕ s was also increased in recurrences of OSCC specimens after radiotherapy. These results suggest that increased myeloid cells or TAMs in tumours or PB may be independent prognostic markers. Local and distant recurrence occurs in approximately 30% of OSCC. Hence, it is crucial to identify novel biomarkers that predict patients at high risk of relapse.
Although several TAM-targeting cancer therapies have been explored, whole TAM depletion may also affect monocyte/macrophage-mediated host defence. Therefore, a M2Mϕ s-specific targeting agent would need to exert high anti-tumour effects with radiation while minimizing toxicity 38 . To our knowledge, there are very few methods of specific molecular targeting for M2Mϕ s. Cieslewicz et al. developed a unique peptide called M2pep that preferentially binds to M2Mϕ s, including TAMs 39 . In this study, we found that M2Mϕ s polarized after radiation highly expressed IL-13Rα 2; therefore, this molecule would be a promising target as a new strategy combined sequentially with radiotherapy. It has been demonstrated that IL13-PE composed of IL-13 and truncated Pseudomonas exotoxin (PE) directly killed IL-13Rα 2 positive cells 40 . Therefore, IL13-PE has the potential to generate synergistic antitumour effects, directly killing tumour cells and specifically ablating protumoural M2Mϕ s.
In summary, our data suggest that local irradiation induces recruitment of CD11b + myeloid cells into OSCC and that these are polarized towards M2Mϕ s shortly before tumours start to regrow. M2Mϕ s rather than CD11 Animals. Female 4-7-week-old BALB/c nude mice weighting 14-18 g were purchased from SLC Japan.
All studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at Yokohama City University.
Isolation of BMDCs.
BMDCs were harvested by flushing the femurs and tibias of female BALB/c nude mice with RPMI1640 Glutamax (Thermo Fisher Scientific) supplemented with 10% FBS using a 25G needle and a syringe. BMDCs were passed through a 70 μ m cell strainer, and red blood cells were removed by NH 4 Cl solution. BMDCs of OSC-19 tumour-bearing mice were obtained from female BALB/c nude mice previously implanted with OSC-19 cells.
Cytokine-stimulated macrophage phenotypic polarization. For BMDC differentiation into BM-derived macrophages (BM-Mϕ s), BMDCs were cultured for an additional 7 days in the same medium supplement with 10 ng/ml recombinant macrophage colony-stimulating factor (M-CSF) (Peprotech). The efficiency of differentiation was confirmed by FACS analysis for CD11b and F4/80 antigen surface expression (Supplementary Fig. S5 ). To induce the macrophage phenotypic polarization, WEHI274.1 cells and BM-Mϕ s were treated for 24 hours with 100 ng/ml IFN-γ (Peprotech) or 200 ng/ml LPS (SIGMA) for M1Mϕ s and 20 ng/ ml IL-4 (R&D systems) or 20 ng/ml IL-13 (Miltenyi Biotec) for M2Mϕ s.
Reverse transcription-PCR. Total RNA was isolated using RNeasy, and reverse transcription was performed using SuperScript TM III Reverse Transcriptase (Thermo Fisher Scientific). PCR with TaKaRa Ex Taq (Takara) was performed with primers (Sigma Genosys), as shown in Supplementary Table S1 [41] [42] [43] [44] [45] . PCR products were viewed using Dolphin-View DV-18 (Kurabou).
Co-culture study. Matrigel Plug assay. Matrigel (growth factor reduced phenol red-free, Corning; 450 μ l) supplemented with 75 ng of basic fibroblast growth factor (bFGF) (Peprotech) was mixed with BM-M2Mϕ s (1 × 10 6 cells) and injected into the flank of female BALB/c nude mice. Matrigel with bFGF served as a control. One week after inoculation, Matrigel plugs were surgically removed, and frozen sections were analysed by immunofluorescence staining for the presence of CD31 endothelial cells.
Quantification of expression.
Quantitative analyses for CD11b, Tie-2, F4/80, Gr-1, VEGFR2, CD68, CD206, iNOS and CD31 were performed by determining the number of positive cells. The signal density of CD31 and pimonidazole were measured using Image J. All analyses were performed in at least three randomly photographed fields using the ×20 or ×40 objectives and ×10 eyepieces of the fluorescence microscope. Three to eight animals per group were used; the error bars shown in the figures indicate SD or SEM.
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Flow cytometric analysis. Mouse whole blood was collected with 1.5% EDTA-2Na used as the anticoagulation agent, and red blood cells were eliminated by a lysing buffer (BD Pharmingen). Leukocyte cells and BMDCs of normal control mice or OSC-19 tumour-bearing mice were stained with CD11b-PE antibody (BD Pharmingen). For IL-13Rα 2 and CD11b double staining, OSC-19 tumours grown at non-IR sites or pre-IR sites in nude mice were minced and enzymatically digested with 3 mg/ml Type VI collagenase and 2 U/ml hyaluronidase (SIGMA). They were further treated with 0.1 mg/ml DNase I (Wako) and 0.09% NH 4 Cl and strained through a 40 μ m cell strainer. Single cells were incubated with IL-13Rα 2-biotin (R&D systems) and CD11b-PE antibodies (BD Pharmingen), followed by Streptavidin-APC antibody (eBioscience). All samples were pre-incubated with Fc-block (BioLegend) prior to staining. Analysis was performed using MoFlo ® Astrios (Beckman Coulter) and Summit Software ver. 4.3 (Beckman Coulter).
Statistical Analysis. Statistical analyses for multiple-group comparison were analysed by one-way ANOVA.
For two-group comparisons, Student's t-test was used (GraphPad Prism software version 5.02). P values (exact significance) less than 0.05 were considered statistically significant.
